|
Vascular Functions of the Plasminogen Activation System.
Arterioscler Thromb Vasc Biol. 2007 Jun; 27(6):1231-7. Epub 2007 Mar 22
William P. Fay, Nadish Garg, and Madhavi Sunkar |
|
Decreased levels of PAI-1 and alpha(2)-antiplasmin contribute to enhanced fibrinolytic activity in divers.
Thromb Res. 2007 May;
Radziwon P, Olszanski R, Tomaszewski R, Lipska A, Dabrowiecki Z, Korzeniewski K, Siermontowski P, Boczkowska-Radziwon B. |
|
Comparison of the effects of pioglitazone and voglibose on circulating total and high-molecular-weight adiponectin, and on two fibrinolysis inhibitors, in patients with Type 2 diabetes.
Diabet Med.. 2007 May; Epub ahead of print May
Aso Y, Yamamoto R, Suetsugu M, Matsumoto S, Wakabayashi S, Matsutomo R, Takebayashi K, Inukai T. |
|
The influence of metabolic syndrome components on plasma PAI-1 concentrations is modified by the PAI-1 4G/5G genotype and ethnicity.
Atherosclerosis. 2007 Abr;
Nitien Hira Naran, Nanthakumarn Chetty and Nigel John Crowther. |
|
Blood inhibitory capacity toward exogenous plasmin.
Blood Coagulation & Fibrinolysis. 2007 Abr; 18(3):241-6.
Agnieszka Banbula; Thomas P Zimmerman; Valery V Novokhatny. |
|
uPAR uPA PAI-1 interactions and signaling: A vascular biologists view.
Thrombosis and Haemostasis. 2007 Ene; 97(3):336-42.
Bernd R. Binder, Judit Mihaly, Gerald W. Prager. |
|
A new recombinant thrombolytic and antithrombotic agent withhigher fibrin affinity a staphylokinase variant - An in-vivo study.
Thrombosis and Haemostasis . 2007 Ene; :1037-1045.
Janusz Szemraj1, Adrian Stankiewicz2, Wioletta Rozmyslowicz-Szermi¡ska2, Andrzej Mogielnicki3,Anna Gromotowicz2, Wlodzimierz Buczko3, Katarzyna Oszajca1, Jacek Bartkowiak 1, Ewa Chabielska2. |
|
Association between the plasminogen activator inhibitor-14G/5G polymorphism and venous thrombosis - A meta-analysis
Thrombosis and Haemostasis. 2007 Ene; :907-13.
Argirios E. Tsantes1, Georgios K. Nikolopoulos2, Pantelis G. Bagos3, Evdoxia Rapti1, Georgios Mantzios1,Violeta Kapsimali4, Anthi Travlou1. |
|
A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) Part II: Enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis.
Thrombosis and Haemostasis. 2007 Ene; 97(1):54-61.
Yi-Xin Wang, Valdeci da Cunha, Jon Vincelette, Lei Zhao, Mariko Nagashima, Kohichi Kawai, Shendong Yuan, Kumar Emayan, Imadul Islam, Junko Hosoya, Mark E. Sullivan, William P. Dole, John Morser, Brad O. Buckman, Ronald Vergona. |
|
Clot structure modification by fondaparinux and consequence on fibrinolysis: A new mechanism of antithrombotic activity.
Thrombosis and Haemostasis. 2007 Ene; 97(1):27-31.
Rémi Varin1, Shahsultan Mirshahi2, Pezhman Mirshahi13, Gerald Kierzek4, David Sebaoun3, Zohar Mishal5, Jean-Pierre Vannier1, Jeanne Yvonne Borg1, Guy Simoneau6, Claudine Soria1, Jeannette Soria3. |
|
Usefulness of Checking Platelet Count Before Thrombolysis in Acute Ischemic Stroke.
Stroke. 2007 Ene; 38:1639-40.
Brett L. Cucchiara, Bryon Jackson, Mark Weiner, and Steven R. Messe. |
|
A novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) Part I: Pharmacological characterization.
Thrombosis and Haemostasis. 2007 Ene; 97(1):45-53.
Yi-Xin Wang, Lei Zhao, Mariko Nagashima, Jon Vincelette, Drew Sukovich, Weiwei Li, Babu Subramanyam, Shendong Yuan, Kumar Emayan, Imadul Islam, Paul Hrvatin, Judi Bryant, David R. Light, Ronald Vergona, John Morser, Brad O. Buckman. |
|
Plasminogen binds to plasmin-modulated factor Xa by Ca2+- and C-terminal lysine-dependent and -independent interactions.
Thrombosis and Haemostasis. 2007 Ene; 97(1):38-44.
Jean E. Grundy1, Mark A. Hancock2, Scott C. Meixner1, Roger C. MacKenzie3, Marlys L. Koschinsky2, Edward L. G. Pryzdial1. |
|
The Roles of Proteinase-Activated Receptors in the Vascular Physiology and Pathophysiology.
Arterioscler Thromb Vasc Biol. 2006 Nov; Epub ahead of print Sep
Hirano K. |
|
Utility of the Fibrinogen/C-Reactive Protein Ratio for the Diagnosis of Disseminated Intravascular Coagulation.
Acta Haematol. 2006 Nov; 117(1):34-39. Epub ahead of print Sep
Kim HK, Lee DS, Kang SH, Kim JQ, Park S, Cho HI. |
|
Human plasma fibrinogen is synthesized in the liver.
Blood. 2006 Nov; Epub ahead of print Oct
Tennent GA, Brennan SO, Stangou AJ, O´grady J, Hawkins PN, Pepys MB. |
|
Management of acute bleeding in a patient with congenital afibrinogenaemia.
Haemophilia. 2006 Nov; 12(6):676-8.
Vakalopoulou S, Rizopoulou D, Zafiriadou E, Perifanis V, Tziomalos K, Lefkou E, Hill M, Dolan G, Garipidou V. |
|
Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis.
Arterioscler Thromb Vasc Biol. 2006 Nov; 26(11):2567-73. Epub 2006 Aug 17 Oct
Collet JP, Allali Y, Lesty C, Tanguy ML, Silvain J, Ankri A, Blanchet B, Dumaine R, Gianetti J, Payot L, Weisel JW, Montalescot G. |
|
Regulation of Fibrinolysis by Thrombin Activatable Fibrinolysis Inhibitor, an Unstable Carboxypeptidase B That Unites the Pathways of Coagulation and Fibrinolysis.
Arterioscler Thromb Vasc Biol. 2006 Nov; 26(11):2445-53. Epub 2006 Sep 7. Oct
Mosnier LO, Bouma BN. |
|
An alternative pathway for fibrinolysis is activated in patients who have undergone cardiopulmonary bypass surgery and major abdominal surgery.
Thromb Res. 2006 Oct; Epub ahead of print Sep
Gando S, Kameue T, Sawamura A, Hayakawa M, Hoshino H, Kubota N. |
